DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Alvespimycin is an investigational drug.
There have been 7 clinical trials for Alvespimycin. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2008.
The most common disease conditions in clinical trials are Breast Neoplasms, Lymphoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Bristol-Myers Squibb, and Institute of Cancer Research, United Kingdom.
Recent Clinical Trials for Alvespimycin
|Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia||National Cancer Institute (NCI)||Phase 1|
|Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer||Bristol-Myers Squibb||Phase 2|
|Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Thera||Bristol-Myers Squibb||Phase 1|